Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine vs. Dexmedetomidine for Tourniquet Induced Hypertension in Knee Arthroscopy
NCT06936410Phase 2Completed
- Sponsor
- Cairo University
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dexmedetomidine, Lidocaine Hydrochloride Injection, without epinephrine in Tourniquet-induced hypertension (TIH), sponsored by Cairo University. Started Mar 2025; status: completed.
02
Drugs
dexmedetomidineLidocaine Hydrochloride Injection, without epinephrine
03
Conditions
Tourniquet-induced hypertension (TIH)
Beyond the preview
Go deeper on NCT06936410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06936410.